ESMO 2021 | Impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for mBC

CDK4/6 inhibitors are a standard treatment approach for patients with HR-positive, HER2-negative metastatic breast cancer, and metastases-directed radiotherapy is commonly utilized alongside palliative or radical schedules during systemic treatment. Icro Meattini, MD, University of Florence, Florence, Italy, discusses the impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for metastatic breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.